Marielle Le Goff

ORCID: 0000-0002-0457-5763
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematological disorders and diagnostics
  • Thermal Regulation in Medicine
  • Autoimmune and Inflammatory Disorders Research
  • Lymphoma Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Pediatric Pain Management Techniques
  • Gastrointestinal Tumor Research and Treatment
  • Respiratory Support and Mechanisms
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Neurological Complications and Syndromes
  • Childhood Cancer Survivors' Quality of Life
  • Long-Term Effects of COVID-19
  • Spinal Dysraphism and Malformations

Centre Jean Bernard
2021-2023

Clinique Victor Hugo
2021

Hôpital Cochin
2017-2018

Assistance Publique – Hôpitaux de Paris
2017-2018

Délégation Paris 5
2018

Université Paris Cité
2017-2018

Institut Pasteur
2017

Evidence regarding the analgesic effect of distraction through immersion in virtual reality (VR) for care-induced pain has been documented several phase 2 trials, but comparison with standard treatments large, randomized studies is needed.In this open-label, multicenter, randomized, 3 trial, we evaluated safety and efficacy a novel VR therapy solution context bone marrow biopsy.Bliss software 4 imaginary interactive environments dimensions binaural sound (head-mounted display). Efficacy...

10.2196/38619 article EN cc-by Journal of Medical Internet Research 2023-01-09

Abstract We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) France, after a maximum follow-up five years. Patients were included according French marketing authorization 2016 (i.e. relapsed or refractory CLL previously untreated deletion 17p and/or tumor protein p53 mutations unsuitable for chemoimmunotherapy) could have initiated more than 30 days prior their enrolment retrospective...

10.1007/s00277-024-05666-3 article EN cc-by Annals of Hematology 2024-03-06

Objectives: Hematologic malignancies may result in multiple organ involvement including pulmonary and renal dysfunctions, the less common acute circulatory failure. We herein addressed outcome of patients with sepsis-like shock related to aggressive hematologic malignancies. Design: A 10-year (2007–2016) monocenter retrospective study. Settings: medical ICU a tertiary care center. Patients: Patients requiring vasopressors who subsequently received chemotherapy. Shock was presumably...

10.1097/ccm.0000000000002990 article EN Critical Care Medicine 2018-01-26

A 68-year-old Caucasian man with mantle cell lymphoma received rituximab, dexamethasone, cytarabine and oxaliplatin (R-DHAOX) induction followed by autologous haematopoietic stem-cell transplantation (HSCT) after carmustine, etoposide, melphalan (BEAM) conditioning. At day 10, he meropenem vancomycin for febrile neutropenia; at 18, developed abdominal pain, a 14·5% weight gain acute hepatitis. Aspartate alanine aminotransferases peaked 39·4 23·3 times the upper limit of normal, respectively;...

10.1111/bjh.15017 article EN British Journal of Haematology 2017-11-27

6573 Background: The prevention of care-induced pain is a central concern for all healthcare teams in hematology units. Use MEOPA (Oxygen + Nitrous Oxide) today standard care relaxation procedure. Distraction through immersion virtual reality (VR) has already documented its analgesic effects several phase II trials but comparison with treatments large randomized study needed. Methods: We conducted an open-label multicenter III trial (ClinicalTrials.gov identifier: NCT03483194). assessed the...

10.1200/jco.2021.39.15_suppl.6573 article EN Journal of Clinical Oncology 2021-05-20

<sec> <title>BACKGROUND</title> Evidence regarding the analgesic effect of distraction through immersion in virtual reality (VR) for care-induced pain, has been documented several phase II trials but comparison with standard treatments large-randomized studies are needed. </sec> <title>OBJECTIVE</title> In this open-label multicenter randomized III trial (ClinicalTrials.gov identifier: NCT 03483194), we evaluated safety and efficacy a novel VR therapy solution context bone marrow (BM)...

10.2196/preprints.38619 preprint EN 2022-04-09
Coming Soon ...